News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioMarker Strategies Awarded $1.5 Million National Cancer Institute Contract to Develop Companion Diagnostic Test to Select Optimal Therapy for Melanoma Patients



9/25/2013 9:43:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BALTIMORE--(BUSINESS WIRE)--BioMarker Strategies today announced that the National Cancer Institute (NCI) has awarded the company a $1.5 million Small Business Innovative Research (SBIR) Phase II contract to develop PathMAP™, a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for individual patients with melanoma.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES